Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation

Lung Cancer, 05/25/2012

Patients harboring both Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation showed differential sensitivities to both targeted therapies, suggesting a variable dependence on EGFR and ALK oncogenes.

Print Article Summary Cat 2 CME Report